Structural Formula (41d7651e B91a 4118 8719 Bf2f663d82a2 01)
Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-0900
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-0900). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)
This text appears to be a table of ADAS-cog change from baseline for different drug treatments and a placebo. The mean change score, clinical improvement, and weeks of drug treatment are included in the table. The text is not readable because it contains several errors and missing information.*
Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)
This data appears to be a graph showing the cumulative percentage of patents for different medications, as well as a chart displaying the change in ADAS-cog scores for different treatment groups and a placebo group. The graph also includes changes from baseline for a medication called Donepezil hydrochloride at 10 mg/day and 5 mg/day.*
Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)
This appears to be a chart showing the percentage of patients who showed improvement or worsening in their condition after treatment with two different doses of Donepezil hydrochloride and a placebo, as measured by the CIBIC-plus rating scale. However, due to the unclear and incomplete nature of the text obtained by , it is difficult to provide a more specific description.*
Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)
This appears to be a table showing the ADAS-cog change from baseline in weeks of drug treatment. The drugs being compared are Donepezil hydrochloride at two different doses and a placebo. There is no information on the extent of clinical improvement seen.*
Figure 5 (41d7651e B91a 4118 8719 Bf2f663d82a2 06)
Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)
This is a table showing the percentage of patients taking either 10mg/day or 5mg/day of Aricept versus placebo and their corresponding ratings on the CIBIC-plus scale for improvement or worsening. The ratings are labeled as Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse.*
Figure 7 (41d7651e B91a 4118 8719 Bf2f663d82a2 08)
Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)
This is a medical prescription of Donepezil Hydrochloride at a dosage of 10 mg/day. The text also includes the term "Piacebo" and some numerical symbols that are not readable. There is also a chart labeled "SIB Change from Baseline".*
Figure 9 (41d7651e B91a 4118 8719 Bf2f663d82a2 10)
Figure 10 (41d7651e B91a 4118 8719 Bf2f663d82a2 11)
Label Image (Lbl713350900)
This is a description of a medication called Donepezil HCI, which is available in a yellow round tablet with the imprint code "HH210". The medication comes in a 10mg dose and is used to treat Alzheimer's disease. The medication should be stored at room temperature between 20°C-25°C (68°F-77°F). It is manufactured by Zhejiang Huahai Pharmaceutical Co. and is available in a package containing 30 tablets. The package has an NDC number of 7133509001 05219301523487 and an expiration date MM/YY.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
